Key result
Baseline serum potassium <3.5 mmol/L is linked to ~49% higher mortality vs 4.0-4.5 mmol/L in HFrEF.
Why the study?
It remains unclear what the safe serum potassium range is in HF and whether it is the same in HFrEF and HFpEF.
Does baseline serum potassium level affect all-cause mortality in patients with heart failure?
Meta-Analysis (n=46,069)
Yes
Does baseline serum potassium level affect all-cause mortality in patients with heart failure?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
The optimal serum potassium concentration in both HFrEF and HFpEF is 4.2-5.0 mmol/L, with hypokalemia (<3.5 mmol/L) strongly associated with worse outcomes in HFrEF.
BACKGROUND AND AIMS: It remains unclear what the safe serum potassium range is in heart failure (HF) and whether it is the same in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). METHODS: A patient-level pooled analysis from 12 randomized controlled trials including 32 346 HFrEF and 13 723 HFpEF patients was performed. Baseline serum potassium level was categorized into six groups (<3.5, ≥3.5-<4.0, ≥4.0-<4.5, ≥4.5-<5.0, ≥5.0-<5.5, and ≥5.5 mmol/L) and serum potassium level at baseline was also analysed as a continuous variable using restricted cubic splines. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, sudden death, pump failure death, first HF hospitalization, and composites of HF hospitalization and cardiovascular or all-cause death. RESULTS: The median follow-up was 24.2 and 36.8 months in HFrEF and HFpEF trials, respectively. In HFrEF, serum potassium levels showed a reverse J-shaped association with outcomes. Compared with ≥4.0-4.5 mmol/L (reference), potassium <3.5 mmol/L was associated with higher risks of all-cause mortality (adjusted hazard ratio 1.49; 95% confidence interval, 1.27-1.76), as well as cardiovascular, sudden, and pump failure death. The lowest risk for all outcomes was observed within the baseline serum potassium range of 4.2-5.0 mmol/L, but even 'mild hyperkalaemia' (5.0-5.5 mmol/L) was not associated with worse outcomes in HFrEF. Although the risk curve was U-shaped and flatter in HFpEF, the lowest incidence of all outcomes was observed over the same potassium range as HFrEF. CONCLUSION: In HFrEF, hypokalaemia is strongly associated with worse outcomes and should be avoided. In terms of safety, the optimal serum potassium concentration in both HFrEF and HFpEF appears to be in the range 4.2-5.0 mmol/L.
Ono et al. (2026) conducted a meta-analysis in Heart failure (HFrEF and HFpEF) (n=46,069). Serum potassium <3.5 mmol/L vs. Serum potassium ≥4.0-4.5 mmol/L was evaluated on All-cause mortality (adjusted HR 1.49, 95% CI 1.27-1.76). Baseline serum potassium <3.5 mmol/L was associated with a higher risk of all-cause mortality compared to 4.0-4.5 mmol/L in HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: